Alluvi, formerly BI 4744, presents a notable advance in obesity treatment. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates remarkable efficacy in research studies, potentially outperforming https://alluvi-healthcare026706.wikibriefing.com/user